Ranbaxy still under attack in India amid WHO all clear
This article was originally published in Scrip
Executive Summary
Ranbaxy continues to be under fire in India, with reports of a prominent pharmacy chain issuing an advisory against its products and the likelihood of a public interest litigation seeking the cancellation of the firm's manufacturing licence coming up for hearing in the Supreme Court next week.